VIPIVOTIDE TETRAXETAN
Prostatic Disease
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Prostatic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DINITROGEN MONOXIDE Beth Israel Deaconess Medical Center | Phase 4 | BB |
Oxygen Beth Israel Deaconess Medical Center | Phase 4 | BB |
Epoetin Alfa Janssen-Ortho Inc., Canada | Phase 3 | B |
Nivolumab Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 | B |
Gnrh Memorial Sloan Kettering Cancer Center | Phase 2 | B |
View all 27 →
Same molecule, other indications
VIPIVOTIDE TETRAXETAN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →